[Risk of axillary recurrence after sentinel lymph node biopsy before neoadjuvant chemotherapy in breast cancer]

Gynecol Obstet Fertil Senol. 2018 Jun;46(6):509-513. doi: 10.1016/j.gofs.2018.05.002.
[Article in French]

Abstract

Objectives: In case of large breast cancer, neoadjuvant chemotherapy (NAC) can be performed to reduce the size of the tumor and thus perform a conservative surgery. The place of the sentinel lymph node biopsy (SLNB) in case of NAC is still debated. The main aim of this study is to assess the risk of axillary recurrence after negative SLNB before NAC.

Methods: It is a retrospective, observational and uni-centric study. We included 18 to 80-year-old patients with unilateral breast cancer requiring a NAC and with a negative SLNB before NAC. Our primary endpoint was axillary recurrence.

Results: Between August 2006 and October 2016, 64 patients had a negative GS performing before a NAC and did not benefit from axillary dissection after NAC. The average duration of follow-up was 37 months. During our follow-up, we did not find any cases of axillary recurrence.

Conclusion: This study supports the reliability of lymph node status assessment using the SLNB before CNA.

Keywords: Axillary recurrence; Breast cancer; Cancer du sein; Chimiothérapie néoadjuvante; Ganglion sentinelle; Neoadjuvant chemotherapy; Récidive axillaire; Sentinel lymph node biopsy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Axilla
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / therapy*
  • Chemotherapy, Adjuvant / methods*
  • Female
  • Humans
  • Lymphatic Metastasis / pathology
  • Middle Aged
  • Neoadjuvant Therapy / methods*
  • Neoplasm Recurrence, Local / epidemiology*
  • Retrospective Studies
  • Risk Factors
  • Sentinel Lymph Node Biopsy / methods*